Holen Sie sich die Stockscreener-App
6.32
5.86%
0.345
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt NVAX?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$5.975
Offen:
$6.05
24-Stunden-Volumen:
6.57M
Relative Volume:
1.11
Marktkapitalisierung:
$1.02B
Einnahmen:
$847.25M
Nettoeinkommen (Verlust:
$-284.86M
KGV:
-2.7598
EPS:
-2.29
Netto-Cashflow:
$-112.35M
1W Leistung:
+0.88%
1M Leistung:
+7.94%
6M Leistung:
-25.24%
1J Leistung:
-28.77%
1-Tages-Spanne:
$6.04
$6.415
1-Wochen-Bereich:
$5.80
$7.50
52-Wochen-Spanne:
$5.01
$23.86
Novavax Inc Stock (NVAX) Company Profile
Firmenname
Novavax Inc
Sektor
Branche
Telefon
240-268-2000
Adresse
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Vergleichen Sie NVAX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
6.295 | 1.02B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
439.42 | 128.45B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.78 | 65.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
558.75 | 40.09B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.50 | 35.67B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ONC
Beigene Ltd Adr
|
230.40 | 27.44B | 3.81B | -644.79M | -669.77M | -6.24 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-02-28 | Eingeleitet | BTIG Research | Buy |
| 2024-07-30 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2024-05-10 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2024-05-10 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2023-08-09 | Hochstufung | B. Riley Securities | Neutral → Buy |
| 2023-04-20 | Herabstufung | TD Cowen | Outperform → Market Perform |
| 2023-03-01 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2023-01-09 | Bestätigt | B. Riley Securities | Buy |
| 2022-12-30 | Bestätigt | H.C. Wainwright | Buy |
| 2022-12-02 | Eingeleitet | Jefferies | Hold |
| 2022-09-22 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-05-20 | Eingeleitet | BofA Securities | Underperform |
| 2022-02-23 | Bestätigt | B. Riley Securities | Buy |
| 2022-02-22 | Fortgesetzt | Jefferies | Buy |
| 2022-01-21 | Eingeleitet | Cowen | Outperform |
| 2021-05-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-14 | Eingeleitet | Jefferies | Buy |
| 2020-08-06 | Bestätigt | H.C. Wainwright | Buy |
| 2020-08-05 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2020-08-05 | Herabstufung | Ladenburg Thalmann | Neutral → Sell |
| 2020-07-16 | Bestätigt | H.C. Wainwright | Buy |
| 2020-07-08 | Herabstufung | Ladenburg Thalmann | Buy → Neutral |
| 2020-06-29 | Bestätigt | B. Riley FBR | Buy |
| 2020-06-29 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-05 | Hochstufung | JP Morgan | Underweight → Neutral |
| 2020-05-28 | Bestätigt | B. Riley FBR | Buy |
| 2020-05-12 | Bestätigt | H.C. Wainwright | Buy |
| 2020-04-30 | Bestätigt | H.C. Wainwright | Buy |
| 2019-11-27 | Fortgesetzt | B. Riley FBR | Buy |
| 2019-08-14 | Bestätigt | H.C. Wainwright | Buy |
| 2019-02-28 | Herabstufung | Piper Jaffray | Overweight → Underweight |
| 2018-12-18 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2018-12-11 | Eingeleitet | Oppenheimer | Outperform |
| 2018-11-26 | Hochstufung | Piper Jaffray | Neutral → Overweight |
| 2018-09-21 | Hochstufung | JP Morgan | Underweight → Overweight |
| 2018-03-29 | Hochstufung | Seaport Global Securities | Neutral → Buy |
Alle ansehen
Novavax Inc Aktie (NVAX) Neueste Nachrichten
Novavax: Initiating Hold Rating After Strong, But Misunderstood Q1 2025 Earnings Beat - Seeking Alpha
JP Morgan Lowers Price Target for NVAX, Maintains Underweight Ra - GuruFocus
Novavax First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Benzinga Bulls And Bears: IBM, Novavax, Arm Holdings — And UK Trade Deal Boosts Markets - Benzinga
JP Morgan Lowers Price Target for NVAX, Maintains Underweight Rating | NVAX Stock News - GuruFocus
Why Novavax (NVAX) is a Top Momentum Stock for the Long-Term - Yahoo Finance
NVAX Stock Gains 12% on Q1 Earnings & Sales Beat, '25 Sales View Up - Yahoo Finance
Analysts Just Shipped An Incredible Upgrade To Their Novavax, Inc. (NASDAQ:NVAX) Estimates - Yahoo Finance
Novavax (NVAX) Faces Price Target Cut Amid Regulatory Concerns | NVAX Stock News - GuruFocus
Novavax: Q1 Earnings Snapshot - New Haven Register
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships ... - Yahoo Finance
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Sur - GuruFocus
Novavax Inc (NVAX) Q1 2025 Earnings Call Highlights: Revenue Surge Amid Strategic Partnerships ... By GuruFocus - Investing.com Canada
Decoding Novavax Inc (NVAX): A Strategic SWOT Insight - GuruFocus
Novavax (NVAX) Sets Sights on Profitability with Strategic Shifts - GuruFocus
Novavax (NVAX) Shares Surge After Upbeat Q1 Results and Raised R - GuruFocus
Health Care Stocks See Mixed Results In Market Movements - Finimize
Novavax projects $1.025B 2025 revenue framework with focus on partnerships - MSN
Novavax (NVAX) Eyes Resolution with FDA for Covid Vaccine Approval | NVAX Stock News - GuruFocus
Novavax says talks with FDA on COVID vaccine approval ongoing calming investor fears - Reuters
Why This Shrinking Covid-19 Vaccine Stock Jumped 30% - Barron's
COVID Vaccine Maker Novavax Stock Soars 16%Here's Why - Yahoo Finance
Novavax Q1 2025 slides: Revenue surges to $667M, company raises full-year guidance By Investing.com - Investing.com South Africa
Novavax (NVAX) Set to Release Q1 Earnings with Strong Revenue Gr - GuruFocus
FDA advisory panel to discuss makeup of updated COVID shots - Seeking Alpha
Novavax Hauls in $666M Q1 Windfall, Boosts FY25 Outlook - Yahoo Finance
Thursday's Top 5 Trending Stocks: What's Going On With D-Wave, Novavax, Carvana? - Benzinga
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated By Stocktwits - Investing.com India
Earnings call transcript: Novavax Q1 2025 Surpasses Expectations with Strong Revenue Growth - Investing.com
Novavax Stock Rallies On Upbeat Q1 Earnings, Revised Full-Year Revenue Forecast: Retail’s Elated - MSN
Novavax earnings beat by $3.36, revenue topped estimates - Investing.com
Novavax stock soars 20% as Q1 results crush estimates By Investing.com - Investing.com Australia
Novavax swings to profit on lower expenses related to COVID shots - WHTC
Novavax rises after massive Q1 beat, guidance raise - MSN
Novavax (NVAX) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
NVAX Earnings: Novavax Stock Soars 33% in Pre-Market on Explosive Q1 Profit - TipRanks
Novavax Q1 2025 slides: Revenue surges to $667M, company raises full-year guidance - Investing.com Australia
Novavax (NVAX) Reports Strong Q1 Earnings Boosted by APA Terminations - GuruFocus
Novavax (NVAX) Exceeds Q1 Expectations with Strong Earnings and Revenue - GuruFocus
Novavax (NVAX) Shares Surge After Upbeat Q1 Results and Raised Revenue Outlook - GuruFocus
Novavax Inc. Q1 2025 Earnings: EPS of $0.71, Revenue Surges to $667 Million, Exceeding Estimates - GuruFocus
Novavax jumps after vaccine maker swings to profit in first quarter - TradingView
Earnings snapshot: Novavax Q1 tops estimates; updates FY25 outlook - Seeking Alpha
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights | NVAX Stock News - GuruFocus
Novavax Swings To Profit As COVID-19 Vaccine Costs Drop - Finimize
NOVAVAX INC SEC 10-Q Report - TradingView
Novavax Reports First Quarter 2025 Financial Results and Operational Highlights - PR Newswire
Novavax, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025 - marketscreener.com
Novavax to Report First Quarter 2025 Financial Results on May 8, 2025 - Longview News-Journal
US FDA advisers to discuss COVID-19 vaccine recommendations on May 22 - marketscreener.com
Finanzdaten der Novavax Inc-Aktie (NVAX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Novavax Inc-Aktie (NVAX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Trizzino John | President and COO |
Mar 07 '25 |
Option Exercise |
0.00 |
28,890 |
0 |
82,015 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 07 '25 |
Option Exercise |
0.00 |
12,223 |
0 |
75,155 |
| Trizzino John | President and COO |
Mar 01 '25 |
Option Exercise |
0.00 |
48,000 |
0 |
76,310 |
| Casey Mark J | EVP, Chief Legal Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
4,000 |
0 |
33,187 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Mar 01 '25 |
Option Exercise |
0.00 |
58,667 |
0 |
91,269 |
| Jacobs John C | President and CEO |
Mar 01 '25 |
Option Exercise |
0.00 |
83,334 |
0 |
175,183 |
| O'Hara Elaine | EVP, Chief Strategy Officer |
Mar 01 '25 |
Option Exercise |
0.00 |
59,600 |
0 |
73,825 |
| Jacobs John C | President and CEO |
Jan 23 '25 |
Option Exercise |
0.00 |
83,196 |
0 |
130,722 |
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
0.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):